362 related articles for article (PubMed ID: 29908090)
21. Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.
Rocco D; Sapio L; Della Gravara L; Naviglio S; Gridelli C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768754
[TBL] [Abstract][Full Text] [Related]
22. A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Yoon H; Kwak Y; Choi S; Cho H; Kim ND; Sim T
J Med Chem; 2016 Jan; 59(1):358-73. PubMed ID: 26652860
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
24. RET fusion gene: translation to personalized lung cancer therapy.
Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K
Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695
[TBL] [Abstract][Full Text] [Related]
25. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
Wang M; Naganna N; Sintim HO
Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
[TBL] [Abstract][Full Text] [Related]
26. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
[No Abstract] [Full Text] [Related]
27. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
28. Predictive molecular pathology in metastatic thyroid cancer: the role of
Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
[TBL] [Abstract][Full Text] [Related]
29. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
[TBL] [Abstract][Full Text] [Related]
30. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
31. Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
Song M
J Med Chem; 2015 May; 58(9):3672-81. PubMed ID: 25625428
[TBL] [Abstract][Full Text] [Related]
32. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
Hu X; Liu X; Khatri U; Wu J
Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
[TBL] [Abstract][Full Text] [Related]
33. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
[TBL] [Abstract][Full Text] [Related]
34. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
[TBL] [Abstract][Full Text] [Related]
35. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.
Jasim S; Ying AK; Waguespack SG; Rich TA; Grubbs EG; Jimenez C; Hu MI; Cote G; Habra MA
Thyroid; 2011 Feb; 21(2):189-92. PubMed ID: 21186952
[TBL] [Abstract][Full Text] [Related]
36. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
37. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
[TBL] [Abstract][Full Text] [Related]
38. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M; Yang D; Lakkaniga NR; Frett B; McConnell N; Zhang L; Brescia A; Federico G; Zhang L; Salerno P; Santoro M; Li HY; Carlomagno F
Sci Rep; 2021 Aug; 11(1):16103. PubMed ID: 34373541
[TBL] [Abstract][Full Text] [Related]
39. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
Gujral TS; Mulligan LM
Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
[TBL] [Abstract][Full Text] [Related]
40. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
